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in this study. Patients admitted with a diagnosis of systemic sepsis (12 patients) were enrolled in the study after obtaining die appropriate informed consent. In addition, patients who developed the sepsis syndrome while in the Intensive Care Unit (14 patients) were also included in the study. The study was approved by our local hospital ethical committee. The severity of the clinical condition was assessed by the APACHE Π scoring system (4) upon admission or upon diagnosis of sepsis syndrome. All patients in this study were Saudi Arabian nationals. The mean age of patients was 54.6 years (range 21-99 years). There was a total of 26 patients in the study group (9 males and 17 females).
Patient who had known pre-existing hypoproteinaemia or hypoalbuminaemia, undernutrition, pregnancy, and myxoedema were alJ excluded from the study. Similarly, patients receiving anti-neoplastic drugs phenothiazines, cimetidine, or procainamide were also excluded from the study. All these conditions are known to increase the serum catalytic concentration of cholinesterase (5) . In addition, patients receiving blood transfusion (but not blood substituents) were excluded from the study. All patients with any clinical or biochemical evidence of pre-existing liver disease were excluded from the study.
The sepsis syndrome (6) in this study was defined according to the criteria of Hammerschmidt et al. (7) . The clinical entity was considered to be present when two or more of the criteria from group (A) and any one criterion from group (B) were observed in a patient belonging to a high risk category.
In brief, Group A criteria were defined as: Group B criteria were defined as: 1. Persistent metabolic acidosis with a standard base excess < 5 mmol/1. 2. Systemic vascular resistance < 800 dynes/S in patients with a pulmonary artery catheter. 3. Otherwise unexplained hypotension with systolic blood pressure < 90 mm Hg for over 2 hours.
The presence of any unexplained deterioration of haemodynamic, respiratory, neurologic, renal, or coagulation quantities was considered strongly corroborative.
Blood samples were obtained by sterile technique using a fresh venipuncture site each time. The blood was split into two tubes, one plain tube for serum collection, and the other a lithium heparin tube for plasma collection. The plasma sample was assayed for general chemistry using an automated analyzer (Hitachi 704 system, Boehringer Mannheim, Germany). The serum was stored at -20 °C for subsequent cholinesterase assay. This latter assay was performed in batches and the samples were stored for a maximum of 8 weeks. Serum cholinesterase was assayed using a Hitachi 704 analyzer utilizing the method ofDietz et al. (8) as modified by den Blaauwen et al. (9) . The assay was performed at 30 °C. Samples showing values greater than 12000 U/l were diluted with 2 volumes of normal saline prior to assay (as suggested by the manufacturer). Controls were included (both high and low). The intra-assay variation was 3% while the inter-assay variation was 7%.
The following constituents were assayed on the collected blood samples once the clinical diagnosis was made: complete blood count, sodium, potassium, urea, creatinine, liver function tests including alaninc aminotransferase, aspartate aminotransferase, alkaline phosphatase, total protein, albumin, prothrombin and activated partial thromboplastin times. In addition, serum cholinesterase was also estimated as described above. Blood samples were drawn daily thereafter for the estimation of the above quantities (whenever possible) up to the first seven days or until the time of the patient's discharge or death, whichever was earlier.
A positive blood culture was not considered necessary for inclusion in this study. However, blood was collected aseptically for aerobic and anaerobic culture on day 1 and as appropriate thereafter as a part of the routine Intensive Care Unit protocol.
Blood was also collected from 66 apparently healthy age and sex matched normal controls to establish the baseline values for serum cholinesterase in the local population. None* of the control patients had known hepatic disease, undernutrition, obesity, myxoedema or pregnancy.
Statistical analysis was performed using the SPSS/PC statistical package loaded onto a personal computer. Since most of the quantities had non-parametric distribution, the Mann-Whitney U test was used for statistical evaluation. When the specific quantity had a normal distribution, the Student t-test was used.
Results Table 1 summarizes the results of the comparison of the catalytic concentration of serial serum cholinesterase obtained from the patient group at the entry of the study on day 1 as compared to the control group. Twelve patients in the study were admitted with the diagnosis of sepsis syndrome and 14 patients developed the sepsis while in the Intensive Care Unit. In the first group, the mean APACHE II score was 26.3 ± 3.46 while in iffe second group the mean APACHE II score upon diagnosis was 29 ± 4.90. There was a very significant difference (P < 0.00001) between the patient group and the control group with serum cholinesterase catalytic concentrations being greatly depressed in the patient group in relation to the control group. This depression was noted throughout the remaining six days of sampling. It should be noted that approximately 20% of patients in each of the seven study days showed a cholinesterase catalytic concentration within the "normal range". It was
Tab. I Comparison between the catalytic concentration of serum cholinesterase in each day of the study and the control value. Values represent median (range). interesting to observe that the same patients also showed similar trends in each of the seven days. Table 2 shows the cumulative data of plasma alanine aminotransferase, alkaline phosphatase, prothrombin time and serum cholinesterase for the patient group in each day of the study (total 7 days). It can be seen from this table that the values of alanine aminotransferase were very modestly elevated at the beginning of the study and tended to come down towards normal baseline values by the 4th day. On the other hand, serum cholinesterase catalytic concentrations were significantly depressed at the beginning of the study and continued to be low throughout the seven day follow-up period. Prothrombin time showed a similar trend to that of cholinesterase since it was prolonged at the beginning and remained so for the seven days of the study. Alkaline phosphatase did not show any significant change from baseline values throughout the study period. Table 3 summarizes the results of analysis of serum cholinesterase catalytic concentrations according to the outcomes (fatal or non-fatal) of the sepsis. A significant difference was observed between the catalytic concentrations of cholinesterase in both groups, the level being lower in those who had fatal outcome compared to those who survived the systemic sepsis syndrome. 
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Discussion
Systemic sepsis syndrome (previously termed septic shock syndrome) is a frequently encountered problem in Intensive Care Unit practice and its incidence may be increasing. While there is little doubt that the main pathogenesis is related to the liberation of endotoxins from Gra/w-negative bacteria, other mechanisms may also be operational (10) . It has been shown previously that early application of aggressive therapy (both supportive and definitive) leads to a reduction in mortality (6) . One major aspect of the systemic sepsis syndrome is the hepatic dysfunction which accompanies it. The objective of this study was to examine the use of the serum cholinesterase level as an indicator of hepatic dysfunction in sepsis syndrome.
Our results have shown that there is a decrease in the catalytic concentration of serum cholinesterase in patients with this syndrome. This decrease was maintained throughout the 7 day study period. This is an important observation, since serum cholinesterase seems to show the depression rather early (day 1) and continues thereafter, suggesting that it may be a useful corroborative marker supporting the clinical diagnosis. It is interesting to note that the serum cholinesterase has a long half-life in circulation (5) . This may suggest that any change in its level should be rather slow after the onset of the sepsis syndrome. However, it is clear from our results that this is not the case, a fact which may be explained by the sensitivity of the biosynthetic mechanism of this enzyme to the effect of systemic sepsis. Other conventional liver function tests such as alanine aminotransferase did not show any reliable pattern of elevation. Prothrombin time, once considered to be a sensitive index of acute liver disease was clearly prolonged yielding information similar to that of cholinesterase. This is expected, since most of the coagulation factors are produced by the liver and have short half-lives (about S-14h), thus showing prolongation in acute liver disease. Plasma alkaline phosphatase, on the other hand, did not show any significant change, an expected observation since biliary obstruction is not a major feature of the systemic sepsis syndrome.
Often, patients with evolving sepsis syndrome may have to undergo emergency surgery of an exploratory or definitive nature. In such cases, suxamethonium (a shortacting depolarising muscle relaxant) is the drug of choice for endotracheal intubation. This drug is dependent on plasma cholinesterase for the timely termination of its action. Fortunately however, the lower catalytic concentration of cholinesterase in these patients is of no clinical significant since as little as 30% of normal enzyme activity is adequate to prevent unacceptably long duration of action (5) . The most common cause of the so-called "suxamethonium apnoea" is not the low catalytic concentrations of the enzyme, but the presence of an atypical enzyme which results from an autosomal recessive gene.
Another aspect of interest was to observe any correlation between the mortality of patients with sepsis syndrome and the catalytic concentration of serum cholinesterase. It is reasonable to assume that patients with more severe sepsis (which was likely to be fatal) should have lower catalytic concentrations of serum· 'cholinesterase than those without mortality. Our results confirmed this. Hence serum cholinesterase seemed to be a reliable prognostic marker in systemic sepsis. If this observation is confirmed in subsequent studies, it carries a clinical implication by helping to predict poor outcome from the outset of the sepsis syndrome in those with low catalytic concentrations and hence such patients will be treated very aggressively from the onset.
This study, by virtue of the limited number of patients involved, is only a preliminary one and further studies involving larger number of patients are needed to substantiate our observations.
